These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10501419)

  • 21. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study.
    Pamuk ON; Balci MA; Donmez S; Tsokos GC
    Lupus; 2016 Jan; 25(1):102-9. PubMed ID: 26345673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage.
    López-Longo FJ; Carol N; Almoguera MI; Olazarán J; Alonso-Farto JC; Ortega A; Monteagudo I; González CM; Carreño L
    Lupus; 2003; 12(11):813-9. PubMed ID: 14667096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
    Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
    Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers.
    Pamuk ON; Akbay FG; Dönmez S; Yilmaz N; Calayir GB; Yavuz S
    Lupus; 2013 Nov; 22(13):1416-24. PubMed ID: 23929639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive disease control in systemic lupus erythematosus.
    Ceccarelli F; Olivieri G; Sortino A; Dominici L; Arefayne F; Celia AI; Cipriano E; Garufi C; Lapucci M; Mancuso S; Natalucci F; Orefice V; Perricone C; Pirone C; Pacucci VA; Spinelli FR; Truglia S; Alessandri C; Sciandrone M; Conti F
    Semin Arthritis Rheum; 2021 Apr; 51(2):404-408. PubMed ID: 33652293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients.
    Houman MH; Smiti-Khanfir M; Ben Ghorbell I; Miled M
    Lupus; 2004; 13(3):204-11. PubMed ID: 15119551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Features of Systemic Lupus Erythematosus in Tunisian Males.
    Sayhi S; Achour TB; Mezri S; Hamdi MS; Nour G; Bilel A; Abdelhafidh NB; Ajili F; Louzir B
    Curr Rheumatol Rev; 2020; 16(2):139-142. PubMed ID: 32423372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.
    Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD
    Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine A in the long-term management of systemic lupus erythematosus.
    Germano V; Picchianti Diamanti A; Ferlito C; Podestà E; Salemi S; Migliore A; D' Amelio R; Laganà B
    J Biol Regul Homeost Agents; 2011; 25(3):397-403. PubMed ID: 22023764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study.
    Appenzeller S; Pereira DA; Costallat LT
    Lupus; 2008 Nov; 17(11):1023-8. PubMed ID: 18852227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
    Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
    Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.